Overview
AchE Inhibitor and Insulin
Status:
Completed
Completed
Trial end date:
2018-12-14
2018-12-14
Target enrollment:
0
0
Participant gender:
All
All
Summary
The investigator will examine the effect of a single dose of pyridostigmine, AchE inhibitor on insulin secretion in healthy subjects. Each subject will undergo an intravenous glucose tolerance test (IVGTT) where IV glucose will be administered and the glucose excursion and insulin secretion response will be evaluated by measuring insulin and glucose at different time points. The test will be carried out twice, once without and once with the administration of a single dose of Pyridostigmine on two separate days. The investigator hypothesizes that inhibiting AChE will potentiate insulin secretion.Phase:
Phase 1Accepts Healthy Volunteers?
Accepts Healthy VolunteersDetails
Lead Sponsor:
University of MiamiCollaborator:
American Diabetes AssociationTreatments:
Cholinesterase Inhibitors
Insulin
Pyridostigmine Bromide
Criteria
Inclusion Criteria:- 18 years and older
Exclusion Criteria:
- BMI >30 Kg/m2
- fasting glucose >100
- Glycohemoglobin (Hemoglobin A1C) 5.7% or more
- History of asthma
- Use of medications that may interfere with glucose metabolism